A therapeutic approach that inhibits the binding of HOX proteins to the PBX cofactor to disrupt tumor-driving mechanisms in cancer cells.

A drug candidate designed to inhibit both the ligand-binding and N-terminal domains of the androgen receptor to address resistance in prostate cancer treatment.